Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026

Author: Benzinga Newsdesk | July 29, 2025 07:41am

Financial update

The following is a summary of the Appendix 4C Cash Flow Report:

The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.
Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and Staff Costs comprised over 90% of the total operating expenditure for the year and quarter.
On July 16, 2025, the Company reported the receipt of $4.58 million for the research and development tax incentive and associated interest for the 2024 financial year.

Posted In: RADX